肺癌免疫治疗的研究进展

以程序性细胞死亡受体1（programmed cell death-1，PD-1）及其配体1（programmed death-ligand 1，PD-L1）抑制剂为代表的免疫治疗已经成为肺癌非常重要的治疗手段，在非小细胞肺癌（non-small cell lung cancer，NSCLC）和小细胞肺癌（small cell lung cancer，SCLC）的治疗中均取得了突破性进展，免疫单药、免疫联合化疗、双免疫联合用药相继取得成功，极大改变了肺癌的治疗形式，使肺癌患者实现长期生存，成为肺癌重要的治疗手段。在不断取得突破的同时，针对肺癌免疫治疗领域也在进行着更深层次的研究，包括用药模式的优化、新靶点药物研发、克服耐药策略的探索等，本文将重点介绍肺癌免疫治疗的相关研究进展。 

Progress in immunotherapy of lung cancer

The immunotherapeutic agents programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are crucial in lung cancer treatment, enabling breakthroughs in the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Immuno-monotherapy, immunotherapy combined with chemotherapy, and dual immunotherapy have been successful and invaluable in reshaping lung cancer treatment, enabling lung cancer patients to achieve long-term survival. Currently, immunotherapy for lung cancer treatment is the focus of in-depth research, with studies optimizing models for drug use, developing new target drugs, and exploring strategies to overcome drug resistance. This review focuses on the development of immunotherapy for lung cancer treatment.